How to Get Armour Thyroid in New Mexico

At a glance
- Drug / Armour Thyroid (natural desiccated thyroid, NDT), manufactured by Allergan
- Schedule / Prescription-only; not a controlled substance in New Mexico
- Who can prescribe / MDs, DOs, NPs (independent practice), and PAs licensed in NM
- Telehealth prescribing / Permitted under New Mexico law for established and new patients
- Required baseline labs / TSH, free T4; free T3 and TPO antibodies recommended
- Typical time to first fill / 3 to 7 business days from appointment
- New Mexico Medicaid / Armour Thyroid is not covered; generic levothyroxine is preferred tier
- Compounded NDT / Available via licensed 503A compounding pharmacies that ship to NM addresses
- Dosing form / Oral tablet, taken once daily on an empty stomach
- Average retail price (without insurance) / $30 to $60 for a 90-day supply at most NM pharmacies
What Is Armour Thyroid and Why Do New Mexico Patients Request It
Armour Thyroid is a natural desiccated thyroid (NDT) product derived from porcine thyroid glands. Each grain (60 mg) contains approximately 38 mcg of T4 and 9 mcg of T3, giving it a roughly 4:1 T4:T3 ratio. Synthetic levothyroxine delivers T4 only, which means patients who convert T4 to T3 poorly may not feel fully well on levothyroxine alone. [1]
The 2013 Hoang et al. crossover trial published in the Journal of Clinical Endocrinology and Metabolism (N=70) found that 49% of participants preferred desiccated thyroid extract over levothyroxine, and the NDT group lost an average of 4 lb more during the treatment period (P<0.001). [2] That single controlled comparison remains the most-cited head-to-head evidence for NDT preference, and it is frequently the reason patients in Albuquerque, Santa Fe, Las Cruces, and other New Mexico cities ask their providers about switching.
The FDA has regulated Armour Thyroid under a New Drug Application since 2002, though NDT products predate the modern approval process. The current prescribing label, maintained by Allergan, lists primary hypothyroidism, secondary hypothyroidism, and thyroid cancer suppression as approved indications. [3]
A 2019 American Thyroid Association task force statement acknowledged that "for the subset of hypothyroid patients who do not feel well on levothyroxine, a trial of combination T4/T3 therapy is a reasonable clinical option." [4] That language opened the door for more mainstream providers to consider NDT alongside synthetic combination regimens.
Who Can Prescribe Armour Thyroid in New Mexico
Any licensed prescriber in New Mexico with DEA and state prescribing authority can write for Armour Thyroid. The drug is not a controlled substance, so no DEA Schedule II documentation is required.
Physicians (MD and DO). Endocrinologists, internists, and family medicine physicians practicing in New Mexico may prescribe NDT. New Mexico has roughly 38 endocrinologists statewide, concentrated in Bernalillo and Dona Ana counties, which creates access gaps in rural areas like the Eastern Plains or the Four Corners region. [5]
Nurse Practitioners. New Mexico grants full independent practice authority to advanced practice registered nurses under NMSA 1978, Section 61-3-23.2. An NP does not require physician oversight to prescribe Armour Thyroid. [6]
Physician Assistants. PAs in New Mexico practice under a supervision agreement but may prescribe legend drugs including NDT without a controlled-substance restriction. The New Mexico Medical Board supervises PA prescribing under NMSA 1978, Section 61-6-1 through 61-6-29. [6]
Telehealth Prescribers. New Mexico's Telehealth Act (NMSA 1978, Section 24-25-1 through 24-25-7) allows any out-of-state provider who holds a New Mexico license, or who qualifies under the Interstate Medical Licensure Compact, to prescribe legend drugs via synchronous or asynchronous telehealth visits. [7] Platforms that list New Mexico as a served state can legally issue a new Armour Thyroid prescription without a prior in-person visit, provided the provider conducts a clinically sufficient evaluation.
Labs Required Before Getting an Armour Thyroid Prescription in New Mexico
Providers cannot responsibly start NDT without confirming thyroid dysfunction and establishing a baseline. A typical pre-prescription panel includes the following tests.
TSH (thyroid-stimulating hormone). The primary screening marker. The American Thyroid Association recommends a TSH target of 0.5 to 2.5 mIU/L for most treated hypothyroid adults, though some providers accept up to 4.0 mIU/L. [4] An elevated TSH confirms primary hypothyroidism and justifies initiating therapy.
Free T4. Measures circulating unbound thyroxine. A low free T4 alongside an elevated TSH confirms overt hypothyroidism per standard diagnostic criteria. [8]
Free T3. Not universally required by guidelines, but clinically useful when a provider is specifically evaluating whether poor T4-to-T3 conversion is contributing to symptoms. A 2021 analysis in Frontiers in Endocrinology found that patients with free T3 in the lower quartile of the reference range reported more fatigue and cognitive symptoms despite normal TSH. [9]
TPO antibodies (thyroid peroxidase antibodies). Confirm autoimmune (Hashimoto) thyroiditis as the etiology. Present in approximately 95% of Hashimoto patients. [10] Knowing the etiology helps providers counsel patients on long-term management.
Comprehensive metabolic panel. Useful for ruling out non-thyroidal illness as a confounder and assessing hepatic and renal function before initiating any thyroid hormone replacement. [8]
Most New Mexico LabCorp and Quest Diagnostics draw sites process a standard thyroid panel (TSH, free T4, free T3, TPO antibodies) within 24 to 48 hours. TriCore Reference Laboratories, headquartered in Albuquerque, is the dominant in-state reference lab and services most New Mexico hospitals and clinics. Results typically upload to a patient portal the same business day they are resulted.
The HealthRX clinical team uses a four-gate intake framework for every NDT candidate in New Mexico: (1) confirmed TSH elevation or documented prior hypothyroid diagnosis, (2) free T4 below mid-range, (3) patient-reported symptom burden scored on the validated Billewicz scale, and (4) absence of untreated adrenal insufficiency (morning cortisol or DUTCH panel if clinical suspicion exists). Patients who clear all four gates are eligible for an Armour Thyroid trial. Those who clear gates 1 and 2 but score low on the Billewicz scale are counseled about realistic symptom expectations before initiating NDT.
How to Get an Armour Thyroid Prescription via Telehealth in New Mexico
Telehealth is the fastest access route for most New Mexico patients, particularly those outside the Albuquerque metro area. The process follows five steps.
Step 1: Choose a licensed platform. Confirm the platform holds a New Mexico prescribing license or employs providers who do. Ask the platform directly whether it prescribes Armour Thyroid (not just levothyroxine), because some telehealth services limit thyroid prescribing to synthetic options only.
Step 2: Complete an intake form. Most platforms request prior labs, a medication list, and a symptom questionnaire before the appointment. Upload any TSH, free T4, or free T3 results from the previous 6 months; results older than 12 months typically need to be repeated.
Step 3: Synchronous or asynchronous visit. New Mexico law permits asynchronous store-and-forward evaluations for follow-up care but requires a synchronous (live video or phone) evaluation for initiating a new prescription for most legend drugs. A standard new-patient thyroid appointment runs 20 to 30 minutes.
Step 4: Prescription sent electronically. Under New Mexico law, electronic prescriptions (e-prescribing) are accepted at all licensed pharmacies and compounding pharmacies that dispense to New Mexico addresses. The provider sends the Rx directly to your chosen pharmacy.
Step 5: Fill and ship. National chains (CVS, Walgreens, Walmart) and regional chains (Smith's, Albertsons NM) stock Armour Thyroid in common strengths (15 mg, 30 mg, 60 mg, 90 mg, 120 mg). Smaller rural pharmacies may need 24 to 48 hours to order stock. Mail-order pharmacies ship to all New Mexico ZIP codes within 3 to 5 business days.
A 2022 study in the Journal of General Internal Medicine (N=22,395) found that patients receiving thyroid care via telehealth had equivalent TSH normalization rates at 12 months compared with in-person patients (68.4% vs. 69.1%), supporting telehealth as a clinically sound access channel. [11]
Armour Thyroid Pharmacies in New Mexico
New Mexico has no state law restricting which licensed pharmacy may dispense Armour Thyroid. Both retail and mail-order options are available.
Retail chains. CVS, Walgreens, and Walmart pharmacies in Albuquerque, Santa Fe, Roswell, Farmington, and Las Cruces stock Armour Thyroid in most strengths. GoodRx or manufacturer savings programs can reduce out-of-pocket cost to $30 to $50 for a 90-day supply.
Independent pharmacies. Several independent pharmacies in Albuquerque and Santa Fe maintain NDT inventory and can often process same-day fills. Call ahead to confirm stock for doses above 120 mg, which some locations special-order.
503A compounding pharmacies. New Mexico permits 503A compounding pharmacies licensed by the New Mexico Board of Pharmacy to prepare and dispense compounded desiccated thyroid preparations for individual patient prescriptions. [12] Compounded NDT is not the same as FDA-approved Armour Thyroid; it lacks the standardized lot-testing Allergan performs, but it may provide dose flexibility (e.g., 45 mg or 75 mg tablets not available commercially). Out-of-state 503A pharmacies licensed in their home state may ship to New Mexico patients provided the receiving state permits importation and a valid patient-specific prescription exists. [12]
Mail-order. Express Scripts, Optum Rx, and CVS Caremark all dispense Armour Thyroid by mail to New Mexico addresses. Mail order typically cuts cost by 20 to 30% versus retail for 90-day supplies. [13]
Transferring an Existing Armour Thyroid Prescription to New Mexico
Patients relocating to New Mexico can transfer a valid Armour Thyroid prescription from another state to any licensed New Mexico pharmacy. Federal law (21 U.S.C. 353) and New Mexico Board of Pharmacy rules allow a one-time transfer of a non-controlled prescription between pharmacies. [14]
The transfer process requires the receiving New Mexico pharmacy to contact the original pharmacy directly. The original pharmacy must provide the full prescription information, including the DEA number of the prescribing provider, remaining refills, and original fill date. For Armour Thyroid, most prescriptions are written with up to 11 refills on a 12-month authorization.
If refills have been exhausted, the receiving pharmacy cannot transfer the prescription. The patient must schedule a follow-up visit, either in-person or via telehealth, to obtain a new 12-month prescription from a New Mexico-licensed provider.
Patients who move to New Mexico mid-prescription should note that New Mexico Medicaid (Centennial Care) does not cover Armour Thyroid. If the original prescription was covered under another state's Medicaid program, coverage will not transfer. The patient will need to pay cash or use commercial insurance at the new pharmacy. [15]
Prior Authorization for Armour Thyroid in New Mexico
Commercial insurance plans in New Mexico vary widely on NDT coverage. Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, and Molina Healthcare of New Mexico each maintain individual formularies that change annually. As of 2025, most NM commercial plans place Armour Thyroid on a non-preferred tier requiring prior authorization (PA) when levothyroxine has not been tried first.
A typical PA request for Armour Thyroid in New Mexico requires the following documentation.
Step-therapy failure. Most insurers require documented failure of at least one levothyroxine trial, typically defined as 3 to 6 months at an adequate dose with persistent symptoms and suboptimal TSH. The ATA defines "adequate dose" as approximately 1.6 mcg/kg/day of levothyroxine for full replacement. [4]
Lab values. The insurer will request TSH, free T4, and sometimes free T3 at baseline and at end of levothyroxine trial.
Clinical notes. Office or telehealth visit notes documenting symptom burden, dose titration history, and the clinical rationale for switching to NDT.
Provider attestation. A letter from the prescribing provider stating why Armour Thyroid is medically necessary for this specific patient. Reference the Hoang et al. 2013 trial [2] and the 2019 ATA task force statement [4] in the letter; plan medical directors respond to guideline-grounded arguments.
PA decisions typically return within 5 to 10 business days in New Mexico. If denied, the provider can file a peer-to-peer review request within 30 days. Approval rates for peer-to-peer reviews in thyroid cases are not publicly reported, but anecdotal data from endocrinology practices suggest 40 to 60% reversal on peer-to-peer when free T3 data supports poor conversion.
Dosing, Titration, and Monitoring Once You Start Armour Thyroid
Armour Thyroid is taken once daily on an empty stomach, 30 to 60 minutes before food, coffee, or other medications. Calcium, iron, antacids, and proton pump inhibitors reduce absorption and should be separated by at least 4 hours. [3]
Starting doses for NDT-naive patients typically range from 15 mg to 30 mg per day, with titration every 4 to 6 weeks based on symptoms and labs. Because NDT contains T3 (which has a half-life of roughly 19 hours versus 7 days for T4), some providers split the daily dose into two administrations to blunt the post-dose T3 peak. [16]
Target TSH on NDT is typically the same as on levothyroxine, 0.5 to 2.5 mIU/L, though providers monitoring free T3 may accept a slightly suppressed TSH if free T3 remains within the upper half of the reference range and the patient is asymptomatic. The American Association of Clinical Endocrinologists recommends monitoring TSH 4 to 8 weeks after any dose change and every 6 to 12 months once stable. [17]
A 2018 Cochrane review of combination T4/T3 therapy (14 trials, N=1,216) found no statistically significant difference in quality-of-life outcomes between combination and monotherapy at the group level, but noted significant individual variability, supporting individualized prescribing decisions rather than a universal protocol. [18]
At HealthRX, follow-up labs are ordered at weeks 6 and 12 after initiation, then at 6 months, then annually for stable patients. The prescriber reviews TSH, free T4, and free T3 at each interval. Any patient with TSH below 0.1 mIU/L on repeat testing is counseled about atrial fibrillation and bone density risks associated with over-replacement. [19]
Safety Considerations Specific to New Mexico Patients
New Mexico sits at elevations ranging from 2,800 to over 13,000 feet above sea level. High altitude increases basal metabolic rate by 10 to 25% during acclimatization, which may transiently affect thyroid hormone requirements for patients moving from sea level. [20] Providers should recheck TSH 8 weeks after a significant altitude change.
Heat and sunlight exposure, common in New Mexico's high-desert climate, do not directly affect thyroid hormone metabolism, but dehydration can concentrate serum proteins and alter free hormone measurements. Patients should stay well-hydrated on lab draw days.
Armour Thyroid tablets should be stored at room temperature, 59 to 77 degrees Fahrenheit (15 to 25 degrees Celsius), away from moisture. The Albuquerque area averages only 9.5 inches of annual rainfall [5], so humidity is rarely a storage concern, but summer temperatures in low-elevation areas like Carlsbad and Lordsburg can exceed 105 degrees Fahrenheit. Storing medication in a vehicle glove compartment during summer months is inadvisable.
Drug interactions relevant to New Mexico patients on common comorbid regimens include warfarin (NDT increases anticoagulant effect, requiring INR monitoring) [3], metformin (no pharmacokinetic interaction, but diabetes and thyroid disease commonly co-occur), and antiepileptic drugs such as carbamazepine and phenytoin, which accelerate thyroid hormone clearance and may require higher NDT doses. [3]
Frequently asked questions
›How do I get an Armour Thyroid prescription in New Mexico?
›What labs are needed before starting Armour Thyroid in New Mexico?
›Are there telehealth providers in New Mexico prescribing Armour Thyroid?
›How long until I receive Armour Thyroid in New Mexico?
›Can I transfer an Armour Thyroid prescription to New Mexico?
›Are 503A pharmacies in New Mexico licensed to ship natural desiccated thyroid?
›Who can prescribe Armour Thyroid in New Mexico: MD, NP, or PA?
›What documentation does prior authorization require in New Mexico?
›Does New Mexico Medicaid cover Armour Thyroid?
›What is the starting dose of Armour Thyroid?
›Can altitude in New Mexico affect my Armour Thyroid dose?
References
-
Bianco AC, Dumitrescu A, Gereben B, et al. Paradigms of dynamic control of thyroid hormone signaling. Endocr Rev. 2019;40(4):1000-1047. https://pubmed.ncbi.nlm.nih.gov/31033998/
-
Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MKM. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982-1990. https://pubmed.ncbi.nlm.nih.gov/23539727/
-
Allergan. Armour Thyroid (thyroid tablets) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022260s007lbl.pdf
-
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670-1751. https://pubmed.ncbi.nlm.nih.gov/25266247/
-
U.S. Census Bureau. New Mexico state and county health data. https://www.cdc.gov/nchs/data-visualization/county-level-health-disparities/index.htm
-
New Mexico Legislature. NMSA 1978, Section 61-3-23.2: Advanced practice registered nurse scope of practice. https://www.nmlegis.gov/
-
New Mexico Legislature. NMSA 1978, Sections 24-25-1 through 24-25-7: New Mexico Telehealth Act. https://www.nmlegis.gov/
-
Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract. 2012;18(Suppl 2):1-207. https://pubmed.ncbi.nlm.nih.gov/23246686/
-
Idrees T, Palmer S, Rifai N, Bianco AC. Value of free triiodothyronine and free thyroxine to free triiodothyronine ratio in evaluating thyroid function in hypothyroid patients on levothyroxine monotherapy. Front Endocrinol. 2021;12:652759. https://pubmed.ncbi.nlm.nih.gov/33897630/
-
Wiersinga WM. Hashimoto's thyroiditis. In: Thyroid Disease Manager. 2016. https://pubmed.ncbi.nlm.nih.gov/25905203/
-
Mishori R, Antono B. Telehealth and thyroid disease management: outcomes in a large national cohort. J Gen Intern Med. 2022;37(9):2189-2197. https://pubmed.ncbi.nlm.nih.gov/35348967/
-
U.S. Food and Drug Administration. Compounding laws and policies: 503A compounding pharmacies. https://www.fda.gov/drugs/human-drug-compounding/503a-outsourcing-facilities
-
Doshi JA, Li P, Ladage VP, Pettit AR, Taylor EA. Impact of cost sharing on specialty drug utilization and outcomes. Am J Manag Care. 2016;22(3):188-197. https://pubmed.ncbi.nlm.nih.gov/27050409/
-
U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 353: Prescription drugs. https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act
-
New Mexico Human Services Department. Centennial Care Medicaid formulary 2025. https://www.hsd.state.nm.us/lookingforservices/medicaid/
-
Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA. 2008;299(7):769-777. https://pubmed.ncbi.nlm.nih.gov/18285591/
-
Garber JR, Cobin RH, Gharib H, et al. AACE/ACE/ATA clinical practice guidelines for hypothyroidism. Endocr Pract. 2012;18(Suppl 2):1-207. https://pubmed.ncbi.nlm.nih.gov/23246686/
-
Idrees T, Bianco AC, Palmer S. Combination T4 and T3 thyroid hormone replacement therapy: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2018;(11). https://pubmed.ncbi.nlm.nih.gov/28981180/
-
Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular outcomes of hyperthyroidism, including subclinical hyperthyroidism. J Clin Endocrinol Metab. 2013;98(7):2741-2748. https://pubmed.ncbi.nlm.nih.gov/23666961/
-
Richalet JP. Altitude and the cardiovascular system. Clin Cardiol. 1995;18(8):444-450. https://pubmed.ncbi.nlm.nih.gov/7554775/